Scarica l'app Stockscreener
36.92
2.79%
-1.011
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Forum
Previsione
Frazionamento azionario
Precedente Chiudi:
$37.93
Aprire:
$37.16
Volume 24 ore:
101.70K
Relative Volume:
0.18
Capitalizzazione di mercato:
$670.15M
Reddito:
$116.88M
Utile/perdita netta:
$-25.09M
Rapporto P/E:
-263.71
EPS:
-0.14
Flusso di cassa netto:
$-20.74M
1 W Prestazione:
-1.63%
1M Prestazione:
-16.09%
6M Prestazione:
+74.99%
1 anno Prestazione:
+66.53%
Intervallo 1D:
$36.62
$37.80
Intervallo di 1 settimana:
$35.79
$38.69
Portata 52W:
$15.50
$52.24
Rigel Pharmaceuticals Stock (RIGL) Company Profile
Nome
Rigel Pharmaceuticals
Settore
Industria
Telefono
650-624-1100
Indirizzo
611 GATEWAY BOULEVARD, SUITE 900, SOUTH SAN FRANCISCO, CA
Confronta RIGL con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
RIGL
Rigel Pharmaceuticals
|
36.92 | 688.48M | 116.88M | -25.09M | -20.74M | -0.14 |
|
VRTX
Vertex Pharmaceuticals Inc
|
463.69 | 118.58B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
749.62 | 79.40B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ARGX
Argen X Se Adr
|
813.59 | 51.18B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
360.48 | 48.88B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ONC
Beone Medicines Ltd Adr
|
339.19 | 37.49B | 4.98B | 69.59M | 525.67M | 0.5197 |
Rigel Pharmaceuticals Stock (RIGL) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-11-05 | Aggiornamento | Jefferies | Hold → Buy |
| 2023-04-03 | Ripresa | Piper Sandler | Neutral |
| 2022-06-09 | Downgrade | Citigroup | Buy → Neutral |
| 2022-06-08 | Downgrade | Cantor Fitzgerald | Overweight → Neutral |
| 2022-06-08 | Downgrade | Piper Sandler | Overweight → Neutral |
| 2022-03-23 | Iniziato | B. Riley Securities | Neutral |
| 2020-11-09 | Downgrade | JP Morgan | Overweight → Neutral |
| 2019-11-15 | Ripresa | Cantor Fitzgerald | Overweight |
| 2019-09-26 | Ripresa | JP Morgan | Overweight |
| 2019-03-01 | Reiterato | Cantor Fitzgerald | Overweight |
| 2018-08-27 | Iniziato | Citigroup | Buy |
| 2018-05-02 | Reiterato | Cantor Fitzgerald | Overweight |
| 2017-12-21 | Ripresa | Piper Jaffray | Overweight |
| 2017-12-15 | Iniziato | Cantor Fitzgerald | Overweight |
| 2017-11-06 | Ripresa | H.C. Wainwright | Buy |
| 2017-03-09 | Reiterato | H.C. Wainwright | Buy |
| 2016-08-31 | Reiterato | H.C. Wainwright | Buy |
| 2016-08-30 | Reiterato | Piper Jaffray | Overweight |
| 2016-07-13 | Iniziato | H.C. Wainwright | Buy |
| 2016-06-13 | Iniziato | Piper Jaffray | Overweight |
| 2016-04-22 | Aggiornamento | JP Morgan | Neutral → Overweight |
| 2013-04-08 | Reiterato | Stifel | Buy |
| 2012-11-29 | Iniziato | UBS | Neutral |
| 2012-11-06 | Reiterato | Oppenheimer | Outperform |
| 2012-03-26 | Iniziato | Canaccord Genuity | Hold |
| 2010-12-10 | Downgrade | MP Advisors | Outperform → Market Perform |
Mostra tutto
Rigel Pharmaceuticals Borsa (RIGL) Ultime notizie
Rigel Pharmaceuticals (NASDAQ:RIGL) Downgraded to "Strong Sell" Rating by Zacks Research - MarketBeat
RIGEL PHARMACEUTICALS INC (NASDAQ:RIGL): A GARP Stock with Affordable Growth and Strong Fundamentals - Chartmill
How The Narrative Around Rigel Pharmaceuticals (RIGL) Is Shifting With Raised Guidance And Cash Flow - Yahoo Finance
Rigel Pharmaceuticals, Inc. (NASDAQ:RIGL) Sees Significant Growth in Short Interest - MarketBeat
Rigel Pharmaceuticals (RIGL) Valuation After New REZLIDHIA Trial And 2026 Revenue Guidance - simplywall.st
Rigel Pharmaceuticals, Inc. (RIGL) Releases Preliminary Results for Q4 2025 - Insider Monkey
Is Rigel Pharmaceuticals (RIGL) 2026 Revenue Guidance Reframing Its Commercial-Led Investment Narrative? - Yahoo Finance
Precision Trading with Rigel Pharmaceuticals Inc. (RIGL) Risk Zones - Stock Traders Daily
New leukemia drug combo enters trial for patients with hard-to-treat AML - Stock Titan
HC Wainwright Has Negative Forecast for RIGL FY2026 Earnings - MarketBeat
Rigel Pharmaceuticals price target raised to $71 from $69 at Citi - TipRanks
10 Best Performing Affordable Stocks Under $40 - Insider Monkey
A Look At Rigel Pharmaceuticals (RIGL) Valuation After Issuing 2026 Revenue Guidance - Yahoo Finance
Equities Analysts Issue Forecasts for RIGL FY2025 Earnings - MarketBeat
Will Rigel Pharmaceuticals Inc stock outperform tech sector in 2025Gap Down & Low Drawdown Trading Strategies - Bộ Nội Vụ
H.C. Wainwright Maintains Rigel Pharmaceuticals(RIGL.US) With Buy Rating, Maintains Target Price $57 - 富途资讯
Rigel Pharmaceuticals, Inc. (NASDAQ:RIGL) Given Consensus Rating of "Moderate Buy" by Analysts - MarketBeat
Rigel Pharmaceuticals (RIGL) Is Down 7.7% After Issuing Detailed 2026 Revenue Mix Guidance – Has The Bull Case Changed? - simplywall.st
Rigel Announces Strong Preliminary 2025 Results and Outlook - TipRanks
Rigel Pharmaceuticals sees FY26 revenue $275M-$290M, consensus $291.58M - TipRanks
Rigel Pharmaceuticals (RIGL) Reports Impressive Financial Results - GuruFocus
Rigel (RIGL) Projects Strong Revenue Growth for 2025 - GuruFocus
Rigel Provides Business Update and 2026 Outlook - marketscreener.com
Why Rigel Pharmaceuticals Inc. stock is popular among millennials2025 Technical Overview & Short-Term Trading Alerts - ulpravda.ru
Rigel Pharmaceuticals (RIGL) Beats Q1 Earnings and Revenue Estimates - sharewise.com
Rigel Pharmaceuticals (NASDAQ:RIGL) Trading Down 5.3%Here's What Happened - MarketBeat
Rigel Pharmaceuticals, Inc. Announces Inducement Grants under NA - GuruFocus
Rigel Pharmaceuticals, Inc. announces inducement grants under Nasdaq Listing Rule 5635(c)(4) - marketscreener.com
Rigel Pharmaceuticals, Inc. Announces Inducement Grants under NASDAQ Listing Rule 5635(c)(4) - StreetInsider
Earnings Risk: Will Rigel Pharmaceuticals Inc. (RI2) stock gain from green policies2025 Price Momentum & Expert Approved Momentum Ideas - Улправда
Is Rigel Pharmaceuticals Inc. stock a buy in volatile markets2025 Major Catalysts & Long-Term Growth Stock Strategies - Улправда
Is Rigel Pharmaceuticals Inc. stock supported by strong cash flows2025 Support & Resistance & Real-Time Sentiment Analysis - ulpravda.ru
Zacks Industry Outlook Highlights Soleno Therapeutics, Nektar Therapeutics, Rigel Pharmaceuticals, Ironwood Pharmaceuticals and Marker Therapeutics - Yahoo Finance
Is Rigel Pharmaceuticals (NASDAQ:RIGL) Using Too Much Debt? - simplywall.st
Onco360® Has Partnered with Rigel Pharmaceuticals to Add Three Therapies to Its Limited Distribution Portfolio - The Manila Times
SYK Inhibitors Market, Drug Price, Sales & Clinical Trials Outlook, 2030Rigel Pharmaceuticals Lea - PharmiWeb.com
Rigel Pharmaceuticals (NASDAQ:RIGL) Trading 8.4% HigherStill a Buy? - MarketBeat
About Us - FinancialContent
Rigel to Present at the 44th Annual J.P. Morgan Healthcare Conference - StreetInsider
Rigel Pharmaceuticals (NASDAQ:RIGL) Stock Rating Upgraded by Zacks Research - MarketBeat
Rigel to Present at the 44th Annual J.P. Morgan Healthcare Conference – Company Announcement - Financial Times
Best Momentum Stocks to Buy for January 6th - Yahoo Finance
Why Analysts Say The Rigel Pharmaceuticals (RIGL) Story Is Shifting After Q3 And 2025 Guidance - Yahoo Finance
Technical Reactions to RIGL Trends in Macro Strategies - Stock Traders Daily
Is Rigel Pharmaceuticals Inc. stock near bottom after decline2025 Year in Review & Growth Focused Entry Reports - moha.gov.vn
What analysts say about Rigel Pharmaceuticals Inc RI2 stockLow Beta Stocks & Low Risk Investment Growth - earlytimes.in
Jhandewalas Foods Limited Earnings Review What Investors Need to KnowHigh Dividend Yield Stocks & See Risk Factors Before Making Any Move - earlytimes.in
Rigel Pharma: Formulating A Game Plan For 2026 - Seeking Alpha
Rigel Pharmaceuticals, Inc. $RIGL Shares Sold by Voya Investment Management LLC - MarketBeat
Pacer Advisors Inc. Buys New Position in Rigel Pharmaceuticals, Inc. $RIGL - MarketBeat
Rigel Gears Up to Report Q3 Earnings: Here's What to Expect - MSN
Rigel Pharmaceuticals Azioni (RIGL) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
4.38%
1.95%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):